Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 260.00
Ask: 263.00
Change: -5.00 (-1.89%)
Spread: 3.00 (1.154%)
Open: 260.50
High: 265.50
Low: 259.00
Prev. Close: 265.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

21 Apr 2021 07:00

RNS Number : 0778W
Synthomer PLC
21 April 2021
 

 

21st April 2021

 

Synthomer plc

 

Q1 Trading Update

 

Stronger underlying trading across all divisions and continued exceptional Nitrile Latex performance

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2021.

 

Strong trading momentum across all businesses

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile Latex business during 2020 have continued through the first quarter of 2021 with overall performance ahead of expectations. Both volumes and unit margins were significantly ahead of prior year driven by exceptional demand as a consequence of the COVID-19 pandemic.

 

Conditions in our SBR latex business also continued to improve, with all segments except paper trading ahead of the comparative period in 2020. Following the strategic review of the European SBR network we completed the consultation in Marl (Germany) and the planned closure of the Oulu (Finland) site at the end of Q1.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the first quarter of 2021. Our consumer facing and industrial end markets have remained robust with our Oil and Gas business improving month on month. Volumes and unit margins were ahead of the comparative period supported by the acquisition of and synergies from OMNOVA and the introduction of low cost capacity in Europe and the US to drive organic growth in differentiated applications.

 

Industrial Specialities and Acrylate Monomers

 

Industrial Specialities also had a good start to the year with activity levels and unit margins significantly ahead of prior year in all major segments including automotive and consumer facing markets. Acrylate Monomers likewise benefitted from improved demand and industry supply issues resulting in a significant uplift in profitability.

 

Reducing Leverage

 

The strong trading performance and cash generation has resulted in a further reduction in proforma net debt:EBITDA to 1.2x at 31st March 2021 with anticipated leverage of less than 1.0x expected by 30th June 2021 (31st December 2020: 1.8x).

 

 

Positive outlook: strong trading increases FY EBITDA expectations

 

Whilst macroeconomic conditions remain uncertain given the ongoing COVID-19 pandemic, we are encouraged by a further strengthening of underlying trading conditions and the strong performances across all our divisions during Q1.

 

Accordingly, the Board now expects 2021 EBITDA to be in excess of £450m reflecting a further rise in the one off profitability of our Nitrile Latex business and the strengthening of the underlying trading conditions. Our expectation that the Nitrile Latex business will return to more normalised levels in 2022 remains unchanged.

 

Conference call

The company will hold a conference call for investors and analysts at 0800 BST today:

 

Dial in number:

UK (Toll free) 0800 640 6441

UK (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

 

Access code: 921802

 

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: +44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: +44 7703 330 269/ +44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIMMATMTTTBAB
Date   Source Headline
12th Mar 20071:00 pmRNSDirector/PDMR Shareholding
7th Mar 20077:01 amRNSFinal Results
6th Mar 20074:04 pmRNSHolding(s) in Company
20th Feb 20074:29 pmRNSNotice of Results
1st Feb 20074:23 pmRNSBlocklisting Interim Review
18th Dec 20062:08 pmRNSVoting Rights and Capital
15th Dec 20067:58 amRNSTrading Statement
4th Dec 200612:49 pmRNSBlocklisting Interim Review
12th Oct 200610:46 amRNSHolding(s) in Company
2nd Oct 20063:20 pmRNSDirector/PDMR Shareholding
8th Sep 20069:01 amRNSDirector/PDMR Shareholding
7th Sep 20067:01 amRNSInterim Results
21st Aug 20063:22 pmRNSNotice of Results
21st Aug 20062:41 pmRNSDirectorate Change
1st Aug 20062:51 pmRNSBlocklisting Interim Review
14th Jul 20063:51 pmRNSNew Chief Executive
7th Jun 200611:14 amRNSDirector/PDMR Shareholding
5th Jun 20067:00 amRNSDisposal of Reabrook Limited
1st Jun 20064:48 pmRNSBlocklisting Interim Review
25th May 20063:11 pmRNSDirector/PDMR Shareholding
25th May 20063:09 pmRNSDirector/PDMR Shareholding
18th May 20064:59 pmRNSResult of AGM
18th May 200612:00 pmRNSAGM Statement
3rd May 200612:28 pmRNSAnnual Information Update
18th Apr 20063:49 pmRNSAnnual Report and Accounts
13th Apr 200611:30 amRNSDirector/PDMR Shareholding
13th Apr 200611:28 amRNSDirector/PDMR Shareholding
21st Mar 200612:05 pmRNSDirector/PDMR Shareholding
16th Mar 20067:01 amRNSFinal Results
20th Feb 20063:44 pmRNSHolding(s) in Company
20th Feb 20062:00 pmRNSAppointment
9th Feb 200612:10 pmRNSNotice of Results
31st Jan 200610:00 amRNSAdditional Listing
30th Dec 200512:00 pmRNSWithdrawal from SO2 business
23rd Dec 200510:14 amRNSDirector/PDMR Shareholding
14th Dec 20057:00 amRNSPre-close Trading Statement
8th Dec 20051:29 pmRNSBlocklisting Interim Review
7th Dec 20058:42 amRNSSale of Autoclenz Limited
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited
15th Nov 20054:54 pmRNSHolding(s) in Company
31st Oct 20059:45 amRNSProposed sale - Autoclenz Ltd
5th Oct 20052:36 pmRNSDirector/PDMR Shareholding
29th Sep 200512:08 pmRNSDirector/PDMR Shareholding
14th Sep 20053:02 pmRNSHolding(s) in Company
17th Aug 20059:50 amRNSNotice of Results
13th Jul 20053:46 pmRNSChief Operating Officer
1st Jul 200511:15 amRNSJames Robinson Consolidation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.